Torsdag 5 December | 06:46:06 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-11-06 13:30 Kvartalsrapport 2025-Q3
2025-08-21 13:30 Kvartalsrapport 2025-Q2
2025-05-08 13:30 Kvartalsrapport 2025-Q1
2025-02-27 08:00 Bokslutskommuniké 2024
2024-12-18 N/A Extra Bolagsstämma 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning STENO 0.00 DKK
2024-05-15 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-22 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-20 - Kvartalsrapport 2023-Q1
2023-06-13 - Extra Bolagsstämma 2023
2023-05-22 - X-dag ordinarie utdelning STENO 0.00 DKK
2023-02-23 - Bokslutskommuniké 2022
2022-11-18 - Extra Bolagsstämma 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning STENO 0.00 DKK
2022-05-19 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-21 - X-dag ordinarie utdelning STENO 0.00 DKK
2021-05-20 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-15 - X-dag ordinarie utdelning STENO 0.00 DKK
2020-05-14 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-26 - Bokslutskommuniké 2019
2019-11-06 - Kvartalsrapport 2019-Q3
2019-08-20 - Kvartalsrapport 2019-Q2
2019-05-07 - Kvartalsrapport 2019-Q1
2019-02-21 - Bokslutskommuniké 2018

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriLäkemedel & Handel
Stenocare är verksamt inom hälsovårdsindustrin. Bolaget är specialiserat inom utveckling av medicinsk cannabis. Stenocare är en av de första aktören att ha påbörjat försäljning av medicinska cannabisoljor i Danmark. Bolaget kommer framöver även vända sig till övriga europeiska marknader med sitt produktutbud. Stenocares huvudkontor ligger i Randers.
2024-05-02 08:00:00

STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO

STENOCARE A/S ("STENOCARE") today announces its results for the period 01.01.2024 - 31.03.2024. The report, which has not been reviewed by the Company's auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/

Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:

"Stenocare has successfully managed to launch new approved products and sales has seen positive growth during Q1 2024"

[]
(KDKK) 01.01.2024 01.01.2023 01.01.2023 01.12.2022
31.03.2024 31.03.2023 31.12.2023 31.12.2022
3 months 3 months 12 months 12 months
Gross sales [1)] 1,356 837 6,923 5,858
Net sales 1,154 808 3,993 4,490
Operating profit -2,469 -3,157 -12,562 -13,215
before depreciation
(EBITDA)
Net financial items -634 -765 -2,876 -1,360
Investment in tangible 0 0 176 936
assets
Result per share (DKK) -0.20 -0.38 -1.26 -1.40

Result per share: The result for the period divided by the average number of shares. Total number of shares as of March 31, 2024, amounted to 18,384,315 (11,676,126). Average number of shares for the first quarter 2024 was 18,384,315 (11,676,126).

1. Gross sales are sales before reduction for returned products.

Highlights during the period

January 2024 - the Company announced that a refinancing agreement was reached covering all existing debt of 8.2 mDKK. As a result, total debt remaining on the balance sheet will be reduced to 5.4. In December the Company completed a directed issue in addition to the exercise of the TO1 warrants with a total of 7.2 mDKK. As a result of these transactions, the Company has now secured the entire anticipated funding and refinancing requirements until break-even which is anticipated by the end of 2024. The remaining funding event (TO2 warrant exercise, due in June 2024) can now be reserved for growth initiatives and further strengthening of the balance sheet.

February 2024 - The Company announced that it has received approval from The Danish Medicines Agency to sell a new THC/CBD medical cannabis oil product to Danish patients. With this, Stenocare has regained the position as the exclusive (only) provider of all three essential oil products under the Danish Pilot Program: THC oil, CBD oil, and now also the new THC/CBD oil. This is considered an important milestone for the company towards doubling sales and achieving break-even in 2024.

March 2024 - The Company announced in November 2023 that the company and its partners had received approval for a new medical cannabis oil product in Australia, set to be available for patients in the first quarter of 2024. In March the new product is officially released and made ready for sale to Australian patients.

Highlights after the period:

April 2024 - The Company announced, that the new Stenocare THC/CBD medical cannabis oil product under the Danish Pilot Program now is available for sales to patients, and Stenocare is the only supplier of THC/CBD oil products under the Pilot. Out of the many suppliers seeking approval to sell their products, Stenocare has been in a clear leadership position from the start of the Pilot in 2018 and is the only supplier of three different medical cannabis oil products under the Pilot.